
    
      This is a Phase 2, multicenter, single-arm, controlled, clinical trial evaluating the
      efficacy and safety of the phosphatidylinositol 3-kinase delta (PI3K-delta) inhibitor GS-1101
      (CAL-101) as therapy for previously treated chronic lymphocytic leukemia.

      This clinical trial (Study GS-US-312-0120) is a single-arm in which compliant subjects from
      GS US-312-0119 -Arm B who experience progression of CLL while receiving single-agent
      ofatumumab therapy are potentially eligible to receive single-agent, open-label GS 1101
      therapy.
    
  